Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rivertop Renewables Begins Contract Manufacturing to Scale-Up Green Chemicals

Published: Tuesday, April 02, 2013
Last Updated: Tuesday, April 02, 2013
Bookmark and Share
Demonstrated capability of breakthrough oxidation technology enables commercial-scale products and advanced testing.

Rivertop Renewables (www.rivertop.com), a Montana-based renewable chemicals company, today announced it has successfully scaled its patented process technology from the lab to pilot manufacturing. Rivertop has contracted with DTI (www.danchemtechnology.com), a custom manufacturer of fine and specialty chemical products based in Danville, Virginia, to pilot the manufacture of Rivertop's sustainable, high performing, cost-competitive, glucarate-based products. Product made in this initial phase of contract manufacturing will be used to fulfill Rivertop's commercial contracts for bio-based corrosion inhibitors. Remaining volumes of manufactured product will be used by the company and its customers to develop and test glucarate applications in a myriad of other industrial and consumer markets.

"Demonstrating the capability of our technology is another key milestone for our company and proof point for our oxidation process," said Jere Kolstad, President of Rivertop. "Contract manufacturing is a critical step along the way to a capital-efficient technology deployment strategy that yields a high return on investment."

Commencing in February 2012, Rivertop's pilot manufacturing has produced numerous batches of glucarate-based products at approximately 850 pounds per run. DTI's unique manufacturing technologies and flexibility enabled the accurate scaling of Rivertop's platform oxidation process. Data derived from these and subsequent runs will enable Rivertop and DTI to scale to a capacity up to 10 million pounds of contract-manufactured product per year. This next scale of production is projected to come online in the fourth quarter of 2012.

"The DTI team is excited to see and support the Rivertop team in reaching another key milestone in their business strategy," said Tim Condron, CEO of DTI. "Both teams worked tirelessly and collaboratively to meet an aggressive project timeline to transition the Rivertop technology from the lab to a manufacturing environment. This is an exciting time for the Rivertop team and we are positive the market will respond well to this new technology."

In addition to starting contract manufacturing, Rivertop is currently undergoing a multi-million dollar expansion of its research and development laboratories, including the construction of a semi-works facility, at its headquarters in Missoula, Montana. Successful contract manufacturing combined with the coming semi-works will enable the company to scale directly from pilot to global scale production in the coming years, removing the need for a costly demonstration plant.

The Department of Energy (DOE) has identified glucaric acid as one of the top 12 chemicals of the future made from renewable sources. Rivertop initially plans to use its glucaric acid products as an effective and cost-competitive replacement for phosphates in the multi-billion dollar markets for global detergent builders, as well as corrosion inhibitors and chelants to protect transportation and industrial infrastructure without damaging water quality. Multiple longer-term opportunities exist in the company's research with advanced biodegradable polymers, adhesives, and other functional materials. Rivertop's platform process is capable of utilizing a wide variety of sugars to produce a large spectrum of green chemicals and bio-based products that possess a range of properties with applications in various markets.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Personality Traits, Psychiatric Disorders Linked to Specific Genomic Locations
Researchers have unearthed genetic correlations between personality traits and psychiatric disorders.
Forensic 3D Documentation of Skin Injuries
In this study, the validity of using photogrammetry for documenting injuries in a pathological context was demonstrated.
3-D Printed Dog’s Nose Improves Vapor Detection
By mimicking how dogs get their whiffs, a team of government and university researchers have demonstrated that “active sniffing” can improve by more than 10 times the performance of current technologies that rely on continuous suction to detect trace amounts of explosives and other contraband.
New Markers for Forensic Body-fluid Identification
University of Bonn researchers have successfully identified specific Micro-RNA signatures to help forensically identify body fluids.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!